Background Inhaled medication is the cornerstone of the pharmacological treatment for
patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler …

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of
death in the world and its incidence and prevalence is on the rise. It is evident that COPD is …

Background Randomized controlled trials indicate that addition of a long-acting muscarinic
antagonist (LAMA) such as tiotropium may improve asthma control and reduce exacerbation …

Background There is an ongoing debate on whether patients with chronic obstructive
pulmonary disease (COPD) seen in real-life clinical settings are represented in randomized …

Background/objectives There have been controversies about whether inhaled
bronchodilators could increase the risk of clinically important tachyarrhythmias. We …

The long-acting anticholinergic agent tiotropium bromide (Spiriva®) is available as a
solution for inhalation via Respimat® Soft Mist™ Inhaler in the EU and various other …

Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg
once daily, which uses a powder formulation; and the newer Respimat Soft Mist Inhaler …

Aim Two inhaler devices (Respimat® and HandiHaler®) are available for tiotropium, a long
acting anticholinergic agent. We aimed to analyze drug utilization, off‐label usage and …

La terapia inhalada con broncodilatadores de acción larga es la base del tratamiento
farmacológico de la EPOC. Con el fin conocer los que ofrecen un mejor control, se realizó …

Long-acting muscarinic receptor (mAChR) antagonists (LAMAs) are likely to be the main
drugs used to treat patients with COPD. They are generally considered “safe” but concerns …